Annals of Hematology

, Volume 91, Issue 8, pp 1161–1174 | Cite as

Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

  • Florian WeissingerEmail author
  • Holger W. Auner
  • Hartmut Bertz
  • Dieter Buchheidt
  • Oliver A. Cornely
  • Gerlinde Egerer
  • Werner Heinz
  • Meinolf Karthaus
  • Michael Kiehl
  • William Krüger
  • Olaf Penack
  • Stefan Reuter
  • Markus Ruhnke
  • Michael Sandherr
  • Hans-Jürgen Salwender
  • Andrew J. Ullmann
  • Dirk T. Waldschmidt
  • Hans H. Wolf
Review Article


More than 18,000 autolgous transplantation were performed in Europe in the year 2009. It as a routine procedure in experienced centres. Even if there is a low mortality rate, infections are a major issue after transplantation, occurring in more than 60 % of the patients. In this review we discuss all aspects of infections after autologous stem transplantation, including epidemiology, diagnostics, therapeutic algorithms, prophylaxis and supportive therapy.


Autologous stem cell transplantation Diagnostics for infection Anti-infective therapy Prophylaxis of infection Supportive therapy for auto-SCT 


  1. 1.
    Bertz H, Auner HW, Weissinger F et al (2003) Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S167–S174PubMedCrossRefGoogle Scholar
  2. 2.
    Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32(6):851–854PubMedCrossRefGoogle Scholar
  3. 3.
    Auner HW, Zebisch A, Ofner P, Sill H, Linkesch W, Krause R (2005) Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases. Ann Hematol 84(8):532–537PubMedCrossRefGoogle Scholar
  4. 4.
    Aksu G, Ruhi MZ, Akan H et al (2001) Aerobic bacterial and fungal infections in peripheral blood stem cell transplants. Bone Marrow Transplant 27(2):201–205PubMedCrossRefGoogle Scholar
  5. 5.
    Blijlevens NM, Donnelly JP, de Pauw BE (2001) Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. Clin Microbiol Infect 7(Suppl 4):47–52PubMedCrossRefGoogle Scholar
  6. 6.
    Ketterer N, Espinouse D, Chomarat M et al (1999) Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 106(2):191–197PubMedCrossRefGoogle Scholar
  7. 7.
    Weaver CH, Hazelton B, Birch R et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86(10):3961–3969PubMedGoogle Scholar
  8. 8.
    Olivieri A, Offidani M, Montanari M et al (1998) Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 83(4):329–337PubMedGoogle Scholar
  9. 9.
    Perez-Simon JA, Martin A, Caballero D et al (1999) Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24(12):1279–1283PubMedCrossRefGoogle Scholar
  10. 10.
    Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ (1996) Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 18(2):265–271PubMedGoogle Scholar
  11. 11.
    Larsson K, Bjorkstrand B, Ljungman P (1998) Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation. Support Care Cancer 6(4):378–383PubMedCrossRefGoogle Scholar
  12. 12.
    Scheid C, Draube A, Reiser M et al (1999) Using at least 5×10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 23(11):1177–1181PubMedCrossRefGoogle Scholar
  13. 13.
    Reich G, Cornely OA, Sandherr M et al (2005) Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 130(2):265–270PubMedCrossRefGoogle Scholar
  14. 14.
    Gil L, Styczynski J, Komarnicki M (2007) Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 35(6):421–427PubMedCrossRefGoogle Scholar
  15. 15.
    Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol 5(5):231–235PubMedGoogle Scholar
  16. 16.
    Krause R, Auner HW, Gorkiewicz G et al (2004) Detection of catheter-related bloodstream infections by the differential-time-to-positivity method and gram stain-acridine orange leukocyte cytospin test in neutropenic patients after hematopoietic stem cell transplantation. J Clin Microbiol 42(10):4835–4837PubMedCrossRefGoogle Scholar
  17. 17.
    Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883PubMedCrossRefGoogle Scholar
  18. 18.
    Horiuchi T, Gondo H, Miyagawa H et al (2005) Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immunol 6(2):162–166CrossRefGoogle Scholar
  19. 19.
    Bochud PY, Chien JW, Marr KA et al (2008) Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 359(17):1766–1777PubMedCrossRefGoogle Scholar
  20. 20.
    de Boer MG, Jolink H, Halkes CJ et al (2011) Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation. PloS One 6(4):e18403PubMedCrossRefGoogle Scholar
  21. 21.
    Molle I, Peterslund NA, Thiel S, Steffensen R (2006) MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 38(8):555–560PubMedCrossRefGoogle Scholar
  22. 22.
    Mullighan CG, Heatley S, Doherty K et al (2002) Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 99(10):3524–3529PubMedCrossRefGoogle Scholar
  23. 23.
    Barton T, Collis T, Stadtmauer E, Schuster M (2001) Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 32(3):391–395PubMedCrossRefGoogle Scholar
  24. 24.
    Reimer P, Kunzmann V, Wilhelm M et al (2003) Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol 82(5):263–270PubMedGoogle Scholar
  25. 25.
    Locasciulli A, Bruno B, Alessandrino EP et al (2003) Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31(4):295–300PubMedCrossRefGoogle Scholar
  26. 26.
    Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE (1997) Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 19(2):143–147PubMedCrossRefGoogle Scholar
  27. 27.
    Salazar R, Sola C, Maroto P et al (1999) Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 23(1):27–33PubMedCrossRefGoogle Scholar
  28. 28.
    Kontoyiannis DP, Marr KA, Park BJ et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091–1100PubMedCrossRefGoogle Scholar
  29. 29.
    Imataki O, Kami M, Kim SW et al (2004) A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant 33(12):1173–1179PubMedCrossRefGoogle Scholar
  30. 30.
    Molina A, Krishnan AY, Nademanee A et al (2000) High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 89(3):680–689PubMedCrossRefGoogle Scholar
  31. 31.
    Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J, Forman SJ (2010) HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant 16(9):1302–1308PubMedCrossRefGoogle Scholar
  32. 32.
    Maertens J, Theunissen K, Verbeken E et al (2004) Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126(6):852–860PubMedCrossRefGoogle Scholar
  33. 33.
    Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M (2002) Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186(9):1297–1306PubMedCrossRefGoogle Scholar
  34. 34.
    Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97(6):1604–1610PubMedCrossRefGoogle Scholar
  35. 35.
    Frere P, Hermanne JP, Debouge MH, de Mol P, Fillet G, Beguin Y (2004) Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant 33(7):745–749PubMedCrossRefGoogle Scholar
  36. 36.
    Bavaro MF (2002) Neutropenic enterocolitis. Curr Gastroenterol Rep 4(4):297–301PubMedCrossRefGoogle Scholar
  37. 37.
    Gomez L, Martino R, Rolston KV (1998) Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis 27(4):695–699PubMedCrossRefGoogle Scholar
  38. 38.
    Gorschluter M, Mey U, Strehl J et al (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75(1):1–13PubMedCrossRefGoogle Scholar
  39. 39.
    Blot F, Nitenberg G, Chachaty E et al (1999) Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 354(9184):1071–1077PubMedCrossRefGoogle Scholar
  40. 40.
    Gaur AH, Flynn PM, Giannini MA, Shenep JL, Hayden RT (2003) Difference in time to detection: a simple method to differentiate catheter-related from non-catheter-related bloodstream infection in immunocompromised pediatric patients. Clin Infect Dis 37(4):469–475PubMedCrossRefGoogle Scholar
  41. 41.
    Seifert H, Cornely O, Seggewiss K et al (2003) Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis. J Clin Microbiol 41(1):118–123PubMedCrossRefGoogle Scholar
  42. 42.
    Ruhnke M, Bohme A, Buchheidt D et al (2012) Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 23(4):823–833Google Scholar
  43. 43.
    Maschmeyer G, Beinert T, Buchheidt D et al (2009) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 45(14):2462–2472PubMedCrossRefGoogle Scholar
  44. 44.
    Harter C, Schulze B, Goldschmidt H et al (2006) Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 37(4):373–379PubMedCrossRefGoogle Scholar
  45. 45.
    Engelhard D, Cordonnier C, Shaw PJ et al (2002) Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 117(2):444–450PubMedCrossRefGoogle Scholar
  46. 46.
    Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRefGoogle Scholar
  47. 47.
    Meisenberg BR, Miller WE, McMillan R et al (1997) Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 15(1):11–17PubMedGoogle Scholar
  48. 48.
    Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589–1596PubMedCrossRefGoogle Scholar
  49. 49.
    Link H, Böhme A, Cornely OA et al (2003) Antimicrobial therapy of unexplained fever in neutropenic patients Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG—German Cancer Society) Ann Hematol 82 (Suppl 2):S105–S117Google Scholar
  50. 50.
    Ozer H, Armitage JO, Bennett CL et al (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18(20):3558–3585PubMedGoogle Scholar
  51. 51.
    Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R (2002) Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 81(7):374–377PubMedCrossRefGoogle Scholar
  52. 52.
    Holmberg LA, Boeckh M, Hooper H et al (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94(12):4029–4035PubMedGoogle Scholar
  53. 53.
    Kohno K, Nagafuji K, Tsukamoto H et al (2009) Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis 11(4):318–323PubMedCrossRefGoogle Scholar
  54. 54.
    Lee MY, Chiou TJ, Hsiao LT et al (2008) Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 87(4):285–289PubMedCrossRefGoogle Scholar
  55. 55.
    Ng AP, Worth L, Chen L et al (2005) Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 90(12):1672–1679PubMedGoogle Scholar
  56. 56.
    Nichols WG, Guthrie KA, Corey L, Boeckh M (2004) Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39(9):1300–1306PubMedCrossRefGoogle Scholar
  57. 57.
    Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M (2009) Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 94(8):1101–1108PubMedCrossRefGoogle Scholar
  58. 58.
    Doucette K, Fishman JA (2004) Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 38(10):1428–1439PubMedCrossRefGoogle Scholar
  59. 59.
    Zihlif M, Khanchandani G, Ahmed HP, Soubani AO (2005) Surgical lung biopsy in patients with hematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. Am J Hematol 78(2):94–99PubMedCrossRefGoogle Scholar
  60. 60.
    Cherif H, Martling CR, Hansen J, Kalin M, Bjorkholm M (2007) Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication. Support Care Cancer 15(12):1393–1398PubMedCrossRefGoogle Scholar
  61. 61.
    Maschmeyer G, Bertschat FL, Moesta KT et al (2003) Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer 39(6):783–792PubMedCrossRefGoogle Scholar
  62. 62.
    Owczuk R, Wujtewicz MA, Sawicka W, Wadrzyk A, Wujtewicz M (2005) Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit. Support Care Cancer 13(5):332–338PubMedCrossRefGoogle Scholar
  63. 63.
    Avery R, Pohlman B, Adal K et al (2000) High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 25(1):67–69PubMedCrossRefGoogle Scholar
  64. 64.
    Arango JI, Restrepo A, Schneider DL et al (2006) Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 37(5):517–521PubMedCrossRefGoogle Scholar
  65. 65.
    Feld R (1999) Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 29(3):503–507PubMedCrossRefGoogle Scholar
  66. 66.
    Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D (1996) Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 18(2):355–359PubMedGoogle Scholar
  67. 67.
    Nucci M, Landau M, Silveira F, Spector N, Pulcheri W (2001) Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 22(10):651–653PubMedCrossRefGoogle Scholar
  68. 68.
    Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431PubMedCrossRefGoogle Scholar
  69. 69.
    Cordonnier C, Chevret S, Legrand M et al (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139(1):8–18PubMedGoogle Scholar
  70. 70.
    McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 15(2):451–457PubMedGoogle Scholar
  71. 71.
    Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L (2006) Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 24(33):5207–5215PubMedCrossRefGoogle Scholar
  72. 72.
    Piccirillo N, Sica S, Laurenti L et al (1999) Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 23(12):1245–1250PubMedCrossRefGoogle Scholar
  73. 73.
    Martino M, Pratico G, Messina G et al (2006) Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 77(5):410–415PubMedCrossRefGoogle Scholar
  74. 74.
    Bucaneve G, Micozzi A, Menichetti F et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987PubMedCrossRefGoogle Scholar
  75. 75.
    Micozzi A, Bucaneve G (2005) Prophylaxis and treatment of bacterial infections: do we need new strategies? Rev Clin Exp Hematol 9(2):E4PubMedGoogle Scholar
  76. 76.
    Reuter S, Kern WV, Sigge A et al (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40(8):1087–1093PubMedCrossRefGoogle Scholar
  77. 77.
    Goodman JL, Winston DJ, Greenfield RA et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845–851PubMedCrossRefGoogle Scholar
  78. 78.
    Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N (1999) Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 28(2):331–340PubMedCrossRefGoogle Scholar
  79. 79.
    Sandherr M, Einsele H, Hebart H et al (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17(7):1051–1059PubMedCrossRefGoogle Scholar
  80. 80.
    Ljungman P, Reusser P, de la Camara R et al (2004) Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33(11):1075–1081PubMedCrossRefGoogle Scholar
  81. 81.
    Huiqiang H, Qingqing C, Tianxin L et al (2009) Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin’s lymphoma single institution experience. Expert Opin Pharmacother 10(15):2399–2406CrossRefGoogle Scholar
  82. 82.
    Ma SY, Lau GK, Cheng VC, Liang R (2003) Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma 44(8):1281–1285PubMedCrossRefGoogle Scholar
  83. 83.
    Borentain P, Colson P, Coso D et al (2010) Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 17(11):807–815PubMedCrossRefGoogle Scholar
  84. 84.
    Matsue K, Aoki T, Odawara J et al (2009) High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 83(4):357–364PubMedCrossRefGoogle Scholar
  85. 85.
    Ljungman P, Engelhard D, de la Camara R et al (2005) Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35(8):737–746PubMedCrossRefGoogle Scholar
  86. 86.
    Ljungman P, Nahi H, Linde A (2005) Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 130(1):96–98PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Florian Weissinger
    • 1
    Email author
  • Holger W. Auner
    • 2
  • Hartmut Bertz
    • 3
  • Dieter Buchheidt
    • 4
  • Oliver A. Cornely
    • 5
  • Gerlinde Egerer
    • 6
  • Werner Heinz
    • 7
  • Meinolf Karthaus
    • 8
  • Michael Kiehl
    • 9
  • William Krüger
    • 10
  • Olaf Penack
    • 11
  • Stefan Reuter
    • 12
  • Markus Ruhnke
    • 13
  • Michael Sandherr
    • 14
  • Hans-Jürgen Salwender
    • 15
  • Andrew J. Ullmann
    • 16
  • Dirk T. Waldschmidt
    • 17
  • Hans H. Wolf
    • 18
  1. 1.Klinik für Innere Medizin, Hämatologie/Onkologie und PalliativmedizinEvangelisches Krankenhaus BielefeldBielefeldGermany
  2. 2.Department of HaematologyImperial College at Hammersmith HospitalLondonUK
  3. 3.Abteilung Innere Medizin IUniversitätsklinikum FreiburgFreiburg im BreisgauGermany
  4. 4.Klinik für Innere Medizin IIIUniversitätsklinikum MannheimMannheimGermany
  5. 5.Klinik I für Innere Medizin und Zentrum für Klinische StudienUniversität zu KölnCologneGermany
  6. 6.Medizinische Klinik VUniversitätsklinikum HeidelbergHeidelbergGermany
  7. 7.Medizinische Klinik und Poliklinik IIJulius-Maximilian-Universität WürzburgWürzburgGermany
  8. 8.Klinik für Hämatologie und OnkologieKlinikum NeuperlachMunichGermany
  9. 9.Medizinische Klinik IKlinikum Frankfurt (Oder)Frankfurt (Oder)Germany
  10. 10.Klinik und Poliklinik für Innere Medizin CErnst-Moritz-Arndt-Universität GreifswaldGreifswaldGermany
  11. 11.Abt. Onkologie und HämatologieCharité Universitätsmedizin-Campus Charité MitteBerlinGermany
  12. 12.Medizinische Klinik 4Klinikum LeverkusenLeverkusenGermany
  13. 13.Medizinische Klinik und Poliklinik IICharité Universitätsmedizin-Campus Charité MitteBerlinGermany
  14. 14.Schwerpunktpraxis für Hämatologie und OnkologieWeilheimGermany
  15. 15.2. Medizinische AbteilungAsklepios Klinik AltonaHamburgGermany
  16. 16.3. Medizinische AbteilungJohannes-Gutenberg-Universität MainzMainzGermany
  17. 17.Klinik I für Innere MedizinUniversität zu KölnCologneGermany
  18. 18.Innere Medizin IVMartin-Luther-Universität Halle-WittenbergHalleGermany

Personalised recommendations